1. Home
  2. NEXN vs LCTX Comparison

NEXN vs LCTX Comparison

Compare NEXN & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexxen International Ltd. American Depository Shares

NEXN

Nexxen International Ltd. American Depository Shares

HOLD

Current Price

$5.96

Market Cap

367.2M

Sector

Technology

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.69

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXN
LCTX
Founded
2007
1990
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
367.2M
407.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NEXN
LCTX
Price
$5.96
$1.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
4
Target Price
$12.00
$4.25
AVG Volume (30 Days)
390.1K
1.2M
Earning Date
03-04-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
237.45
N/A
EPS
0.62
N/A
Revenue
$376,353,000.00
$10,816,000.00
Revenue This Year
$5.43
$6.32
Revenue Next Year
N/A
$124.49
P/E Ratio
$9.55
N/A
Revenue Growth
7.80
24.05
52 Week Low
$5.72
$0.37
52 Week High
$12.60
$2.09

Technical Indicators

Market Signals
Indicator
NEXN
LCTX
Relative Strength Index (RSI) 31.44 48.58
Support Level $5.72 $1.64
Resistance Level $6.90 $1.79
Average True Range (ATR) 0.23 0.08
MACD -0.02 0.00
Stochastic Oscillator 20.33 44.23

Price Performance

Historical Comparison
NEXN
LCTX

About NEXN Nexxen International Ltd. American Depository Shares

Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: